Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMEM97 | Q5BJF2 | 8/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 3/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4486121 | 0.92 | TMEM97 (0.43) | TMEM97SIGMAR1ACHEBCHELTA4H | |
| SCHEMBL4491553 | 0.91 | LIMK1 (0.37) | TMEM97SIGMAR1MCHR1LRRK2 | |
| SCHEMBL4491548 | 0.91 | LIMK1 (0.37) | TMEM97SIGMAR1MCHR1LRRK2 | |
| SCHEMBL4487240 | 0.90 | BACE1 (0.38) | TMEM97SIGMAR1ACHEBCHELTA4H | |
| SCHEMBL4485494 | 0.88 | KDM4E (0.37) | TMEM97SIGMAR1LRRK2 | |
| SCHEMBL4485489 | 0.88 | KDM4E (0.37) | TMEM97SIGMAR1LRRK2 | |
| SCHEMBL4504536 | 0.88 | ROCK2 (0.37) | LRRK2 | |
| SCHEMBL4504528 | 0.88 | ROCK2 (0.37) | LRRK2 | |
| SCHEMBL4487655 | 0.87 | TMEM97 (0.45) | TMEM97SIGMAR1ACHEBCHELTA4H | |
| SCHEMBL4487652 | 0.87 | TMEM97 (0.45) | TMEM97SIGMAR1ACHEBCHELTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514468-B2 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-04-07 | — | — | US | disclosed |
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194813-A1 | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions | KDR, FLT1, EGFR | TMEM97 2293/4885SIGMAR1 916/4885ACHE 2967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.